Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

242
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
242
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

387
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
387
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

685
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
685
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

797
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
797
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

538
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
538
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

274
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Adipokines and Potential Oxidative Stress-Related Mechanisms Linking MASLD with Subclinical Atherosclerosis Within CKM Syndrome: A Systematic Review and Meta-Analysis.

Antioxidants (Basel, Switzerland)·2026
Same author

Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical and Histopathological Profile of Adults with Celiac Disease at Diagnosis and on a Gluten-Free Diet: A Cross-Sectional Observational Study.

Clinics and practice·2026
Same author

Clinical and Comorbidity-Related Factors Associated with Health-Related Quality of Life in Patients with Heart Failure: A Cross-Sectional Study.

Journal of clinical medicine·2026
Same author

Adipokines and Vascular Modulators in CKM: Emerging Biomarkers as Diagnostic and Therapeutic Targets.

International journal of molecular sciences·2025
Same author

Metabolic Characteristics and Cytokine Gene Polymorphisms as Potential Risk Factors for a Higher Liver Fibrosis Stage in MASLD Patients: A Hospital-Based Study.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Dec 27, 2025

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

16.4K

Uric Acid and Arterial Stiffness.

Adriana Albu1, Ioana Para2, Mihai Porojan1

  • 12nd Department of Internal Medicine.

Therapeutics and Clinical Risk Management
|February 26, 2020
PubMed
Summary
This summary is machine-generated.

High uric acid (UA) levels are linked to cardiovascular issues. This review examines how UA affects arterial stiffness and if UA-lowering drugs can improve vascular health.

Keywords:
arterial stiffnesscardiovascular riskuric acid

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.6K
Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy
10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

11.0K

Related Experiment Videos

Last Updated: Dec 27, 2025

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

16.4K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.6K
Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy
10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

11.0K

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Metabolic Disorders

Background:

  • Hyperuricemia is frequently observed alongside hypertension, diabetes mellitus, metabolic syndrome, and chronic kidney disease.
  • Epidemiological data suggest a correlation between elevated uric acid (UA) levels and cardiovascular diseases.
  • Potential mechanisms linking hyperuricemia to cardiovascular disease include increased oxidative stress and systemic inflammation.

Purpose of the Study:

  • To review epidemiological studies on the association between uric acid (UA) and arterial stiffness.
  • To highlight findings from interventional studies assessing arterial stiffness in patients receiving UA-lowering therapies.

Main Methods:

  • Systematic review of epidemiological research investigating UA and arterial stiffness.
  • Analysis of interventional studies evaluating changes in arterial stiffness parameters after UA-lowering drug treatment.

Main Results:

  • Epidemiological studies provide evidence for a relationship between increased UA and vascular alterations, though not definitively confirmed.
  • Interventional studies offer insights into the potential impact of UA reduction on arterial stiffness.

Conclusions:

  • Arterial stiffness may represent a pathway through which hyperuricemia contributes to cardiovascular disease.
  • Further research is needed to fully elucidate the UA-arterial stiffness connection and the therapeutic potential of UA-lowering drugs.